New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes
Elsa Maitre,Philippe Bertrand,Catherine Maingonnat,Pierre-Julien Viailly,Margaux Wiber,Dina Naguib,Véronique Salaün,Edouard Cornet,Gandhi Damaj,Brigitte Sola,Fabrice Jardin,Xavier Troussard
DOI: https://doi.org/10.18632/oncotarget.25601
2018-06-22
Oncotarget
Abstract:Classical hairy cell leukemia (HCL-c) is a rare lymphoid neoplasm. <i>BRAF<sup>V600E</sup></i> mutation, detected in more than 80% of the cases, is described as a driver mutation, but additional genetic abnormalities appear to be necessary for the disease progression. For cases of HCL-c harboring a wild-type <i>BRAF</i> gene, the differential diagnosis of the variant form of HCL (HCL-v) or splenic diffuse red pulp lymphoma (SDRPL) is complex. We selected a panel of 21 relevant genes based on a literature review of whole exome sequencing studies (<i>BRAF</i>, <i>MAP2K1</i>, <i>DUSP2</i>, <i>MAPK15</i>, <i>ARID1A</i>, <i>ARID1B</i>, <i>EZH2</i>, <i>KDM6A</i>, <i>CREBBP</i>, <i>TP53</i>, <i>CDKN1B</i>, <i>XPO1</i>, <i>KLF2</i>, <i>CXCR4</i>, <i>NOTH1</i>, <i>NOTCH2</i>, <i>MYD88</i>, <i>ANXA1</i>, <i>U2AF1</i>, <i>BCOR</i>, and <i>ABCA8</i>). We analyzed 20 HCL-c and 4 HCL-v patients. The analysis of diagnostic samples mutations in <i>BRAF</i> (<i>n</i> = 18), <i>KLF2</i> (<i>n</i> = 4), <i>MAP2K1</i> (<i>n</i> = 3), <i>KDM6A</i> (<i>n</i> = 2), <i>CDKN1B</i> (<i>n</i> = 2), <i>ARID1A</i> (<i>n</i> = 2), <i>CREBBP</i> (<i>n</i> = 2) <i>NOTCH1</i> (<i>n</i> = 1) and <i>ARID1B</i> (<i>n</i> = 1). <i>BRAF<sup>V600E</sup></i> was found in 90% (18/20) of HCL-c patients. In HCL-c patients with <i>BRAF<sup>V600E</sup></i> , other mutations were found in 33% (6/18) of cases. All 4 HCL-v patients had mutations in epigenetic regulatory genes: <i>KDM6A</i> (<i>n</i> = 2), <i>CREBBP</i> (<i>n</i> = 1) or <i>ARID1A</i> (<i>n</i> = 1). The analysis of sequential samples (at diagnosis and relapse) from 5 patients (2 HCL-c and 3 HCL-v), showed the presence of 2 new subclonal mutations (<i>BCOR<sup>E1430X</sup></i> and <i>XPO1<sup>E571K</sup></i> ) in one patient and variations of the mutated allele frequency in 2 other cases. In the HCL-v disease, we described new mutations targeting <i>KDM6A</i> that encode a lysine demethylase protein. This opens new perspectives for personalized medicine for this group of patients.